Retinal transplantation studies
Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.
Search
Search results
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Beware of online adverts about treatments
The Retina UK community is sometimes targeted by adverts online or in social media, offering invasive treatments for inherited sight loss.
New mechanism of disease discovered for Retinitis Pigmentosa
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Look Forward – Summer 2023 – Issue 180
Did you join either of our Conferences this year? You can read about them inside this edition of Look Forward. We’ve had some fantastic feedback from our delegates so if you weren’t able to attend, you can watch or listen to the recordings from the day on our website.
SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Meet a Researcher: Hajrah Sarkar
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
Meet a Researcher: Elena Piotter
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.